News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation - October

Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% label

AR-13324-CS205 Clinical Pilot Study Topline Results

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer
  DURHAM, N.C. --(BUSINESS WIRE)--Oct. 7, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
  DURHAM, N.C. --(BUSINESS WIRE)--Sep. 25, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union
European Commission Decision Anticipated In Approximately Two Months DURHAM, N.C. --(BUSINESS WIRE)--Sep. 20, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
View HTML
Toggle Summary Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S. Food and Drug Administration to Allow Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in its Athlone Ireland Facility
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 19, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
TOP